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Rates of hospital-acquired staphylococcal infection in-
creased throughout the 1990s; however, information is limit-
ed on trends in community-onset staphylococcal disease in 
the United Kingdom. We used Hospital Episode Statistics to 
describe trends in hospital admissions for community-onset 
staphylococcal disease and national general practice data 
to describe trends in community prescribing for staphylo-
coccal disease. Hospital admission rates for staphylocco-
cal septicemia, staphylococcal pneumonia, staphylococcal 
scalded-skin syndrome, and impetigo increased >5-fold. 
Admission rates increased 3-fold for abscesses and cel-
lulitis and 1.5-fold for bone and joint infections. In primary 
care settings during 1991–2006, ﬂ  oxacillin  prescriptions 
increased 1.8-fold and fusidic acid prescriptions 2.5-fold. 
The increases were not matched by increases in admis-
sion rates for control conditions. We identiﬁ  ed a previously 
undescribed but major increase in pathogenic community-
onset staphylococcal disease over the past 15 years. These 
trends are of concern given the international emergence of 
invasive community-onset staphylococcal infections.
H
armless colonization of the nasal membranes and skin 
with Staphylococcus aureus is common in the com-
munity (1), but the organism can also cause a variety of 
infections (2). S. aureus is the most common cause of skin 
and soft tissue infections, including wound infections, ab-
scesses, furuncles, carbuncles (3), and impetigo (4) and is 
a major cause of cellulitis (5). It can also cause deep-seated 
infections such as osteomyelitis (6), endocarditis, pneumo-
nia, and septicemia (2). Toxigenic strains can cause toxic 
shock, staphylococcal scalded-skin syndrome (SSSS), and 
staphylococcal food poisoning (2).
More than 70 different potential virulence factors have 
been identiﬁ  ed in S. aureus, including adhesins, exoen-
zymes, and exotoxins (7). Exfoliative toxins are associated 
with impetigo and SSSS (8), and production of Panton-
Valentine leukocidin (PVL) toxin has been associated with 
invasive strains that cause abscesses, bone and joint infec-
tion, and pneumonia (9,10). In the 1950s, PVL production 
was associated with particularly invasive infections caused 
by the penicillin-resistant phage-type 80/81 strain (11,12). 
More recently, in 2006, a review of data on isolates referred 
to the Health Protection Agency’s Staphylococcal Refer-
ence Unit identiﬁ  ed 27 deaths in 27 months from infec-
tions with invasive PVL-positive S. aureus. These deaths 
were in previously healthy people with community-onset 
pneumonia, bacteremia, or severe skin and soft tissue in-
fection (13). Most were caused by methicillin-sensitive S. 
aureus (MSSA) strains. In view of these data and the wider 
concern about emerging community-onset methicillin-
resistant S. aureus (MRSA) (14–16), we sought to deter-
mine whether there had been a generalized increase in 1) 
community-onset staphylococcal disease severe enough to 
merit hospitalization and 2) general practice (GP) antimi-
crobial drug prescribing for skin and soft tissue infections 
putatively caused by staphylococci.
Methods
We analyzed Hospital Episode Statistics (HES) to 
identify trends in admissions for community-onset disease 
that were likely to be caused by pathogenic staphylococci. 
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HES has been operating nationally, recording all admis-
sions to NHS hospitals, since 1989. Inpatient admissions 
are coded by professional coders who used the International 
Classiﬁ  cation of Diseases (ICD) version 9 before 1995 and 
version 10 subsequently. The main reason for admission is 
recorded as the “primary diagnostic code.” HES data have 
been widely used to examine time trends in disease and 
variations in practice and to make international compari-
sons (www.hesonline.nhs.uk).
We developed ICD-9 and ICD-10 code lists for the 
following infections: staphylococcal septicemia, staphy-
lococcal pneumonia, abscess, furuncle, carbuncle, celluli-
tis, impetigo, bone and joint infections, and SSSS (Table 
1). These infections were chosen because S. aureus is the 
identiﬁ  ed or most likely causative organism (or, in the 
case of cellulitis, 1 of the most important organisms). We 
then obtained HES data extracts on admissions to hospi-
tals where the primary diagnosis was 1 of these codes. 
These data covered all NHS hospitals in England from the 
1989–1990 ﬁ  nancial year to the 2003–2004 ﬁ  nancial year 
(April 1 to the following March 31). Abscess and cellulitis 
codes were not well discriminated in ICD-9; many codes 
both identiﬁ  ed abscess and cellulitis and thus precluded 
separate analysis before 1995. In ICD-10, the codes for 
abscess and cellulitis are separated. There was no code 
for SSSS in ICD-9, precluding analysis of trends for this 
condition before 1995.
We obtained annual population denominator data from 
the Ofﬁ  ce for National Statistics (www.statistics.gov.uk) 
and used these to calculate 1) age-speciﬁ  c annual rates of 
admission for the different infections and 2) age-speciﬁ  c 
rate ratios comparing rates in 2003–04 with those in 1989–
90 or, where data before 1995 were not available because 
of coding changes (abscesses, cellulitis, and SSSS), com-
paring rates in 2003–04 with those in 1995–96. We calcu-
lated 95% conﬁ  dence intervals (CIs) by the delta method. 
We calculated annual age-standardized admission rates by 
using indirect standardization; the population of England in 
the earliest year of the trend was used as the baseline popu-
lation (1989–90 for most staphylococcal conditions but 
1995–96 for abscess, cellulitis, and SSSS). Standardized 
admission ratios and 95% CIs comparing 2003–04 rates 
with those in the earliest year of the trend were calculated 
by using indirect standardization to the baseline population 
(17). Age standardization was used to account for the fact 
that the age structure of the population had changed over 
the study period and to allow valid comparison of rates in 
different years.
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Table 1. Comparison of trends in hospital admissions, England, 1989–90 to 2003–04* 
Type of infection and ICD codes 
No. admissions  
(age-standardized admission  
rate per 100,000 population)
Standardized admission 
ratios (95% CI)
Acute community-onset infections likely to be caused by 
staphylococci (ICD-9: ICD-10 codes)  1989–90 2003–04 2003–04 vs. 1989–90
  Abscess, carbuncle, and furuncle and/or cellulitis  
  (6800–6811, 6819–6829: L02.0–L03.9)
23,884 (50.0) 74,447(148.8) 2.98 (2.96–3.00)
  Bone and joint infection (7300–7309, 7110: M86.0– 
  M86.6, M86.8, M86.9, M00.0–M00.2,M00.8,M00.9)
4,104 (8.9) 6,700 (13.4) 1.57 (1.53–1.60)
  Staphylococcal septicemia (381: A41.0–A41.2) 249 (0.5) 1,681 (3.3) 6.39 (6.10–6.71)
 Impetigo  (684: L01.0,L01.1) 199 (0.4) 1,108 (2.5) 5.92 (5.58–6.28)
  Staphylococcal pneumonia (4824: J15.2) 109 (0.2) 568 (1.2) 5.04 (4.64–5.47)
1995–96 2003–04 2003–04 vs. 1995–96
  Cellulitis (NA: L03.0–L03.9) 24,388 (50.3) 49,980 (98.9) 1.97 (1.95–1.98)
  Abscess, carbuncle, and furuncle (NA: L02.0–L02.9) 12,675 (26.1) 24,467 (49.3) 1.89 (1.86–1.91)
  Staphylococcal scalded-skin syndrome (NA: L00.X) 149 (0.3) 747 (1.6) 5.27 (4.91–5.63)
Acute community-onset control conditions (ICD-9: ICD-10 codes) 1989–90 2003–04 2003–04 vs. 1989–90
  Forearm fracture (8130–8135:S520–S529) 30,272 (63.2) 54,089(106.9) 1.69 (1.01–1.68)
  Acute appendicitis (5400–5409, K35.0–K35.9) 30,946 (64.6) 30,324 (61.5) 0.95 (0.94–0.96)
  Ingrown toenail (7030:L60.0) 16,606 (34.7) 11,182 (22.7) 0.65 (0.64–0.67)
  Other septicemias (380–384, 388,389: A400–A409,  
  A414, A415, A418, A419
3,793 (7.9) 12,873 (24.9) 3.15 (3.10–3.20)
  Gastroenteritis/diarrhea of presumed infectious origin  
 (91:  A09.X)
8,416 (17.6) 6,528 (14.3) 0.81 (0.79–0.83)
  Cholecystitis (5750: K81.0) 3,171 (6.6) 4,264 (8.3) 1.25 (1.21–1.28)
  Conjunctivitis (3720–3724:H10.0–H10.9) 639 (1.3) 193 (0.3) 0.33 (0.29–0.38)
  Viral pneumonia (4800–4809:J12.0–J12.9) 585 (1.2) 501 (1.1) 0.88 (0.81–0.96)
  Erysipelas (35:A46.X) 373 (0.8) 357 (0.7) 0.89 (0.80–0.99)
*Years are financial years, April 1 to March 31. CI, confidence interval; ICD, International Classification of Diseases; NA, not available. RESEARCH
To verify that observed trends were not part of a gener-
alized increase in hospital admissions, we used HES data to 
examine trends in the following control conditions: appen-
dicitis, cholecystitis, conjunctivitis, fractured forearm, gas-
troenteritis/diarrhea of presumed infectious origin, ingrown 
toenail, and erysipelas. These conditions were chosen as 
examples of acute community-onset conditions that are 
not normally caused by staphylococci. We also examined 
trends in hospitalizations for septicemia in which staphylo-
cocci were not identiﬁ  ed as the causative organism.
We analyzed data from the Prescription Prescribing 
Authority, which collects information on all prescriptions 
issued by general practitioners and dispensed by com-
munity pharmacists and dispensing general practitioners 
(PACT data). The information collected includes the name 
of the drug and the number of items dispensed (an item is 
deﬁ  ned as each preparation on the prescription). The data 
cannot be linked routinely to patient demographic or clini-
cal data. Hence, they cannot be used to calculate age- and 
sex-speciﬁ  c prescribing rates or to look at prescribing rates 
for speciﬁ  c conditions (18). We obtained data on all GP 
prescriptions of ﬂ  oxacillin (including co-ﬂ  uampicil) and 
fusidic acid (excluding Fucidin eyedrops but including 
combined steroid and fucidic acid preparations) for Eng-
land from 1991 through 2006. We focused on prescriptions 
of ﬂ  oxacillin and fusidic acid because staphylococcal infec-
tion is the only indication given for these conditions in the 
British National Formulary. We used national population 
data to calculate crude annual prescribing rates. Analyses 
used anonymous aggregate data and did not require ethical 
approval.
Results
For all staphylococcal diseases from 1990–2001 to 
2003–04, we found increasing admission trends. These 
trends are illustrated in Figure 1, panel A, which shows 
age-standardized hospital admission ratios for suspected 
staphylococcal disease, and in Table 1, which compares 
the number of admissions and standardized admission rates 
in baseline periods and in 2003–04 and shows the stan-
dardized admission ratios. For staphylococcal septicemia, 
staphylococcal pneumonia, impetigo, and SSSS, increases 
in admission rates were >5-fold over the study period; for 
abscesses, furuncles, carbuncles, and cellulitis, the increas-
es were nearly 3-fold; for bone and joint infections, the 
increase was >50%. There were no similar increases in ad-
mission rates for the control conditions in general, although 
there was a 3-fold increase in admissions for septicemia 
not attributed to staphylococci (Table 1; Figure 1, panel 
B). However, most septicemias recorded in HES have no 
causative organism speciﬁ  ed (68% in 1989–90 vs. 65% in 
2003–04), and many of these will in fact have been caused 
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Figure 1. A) Age-standardized admission ratios for 
community-onset infections identiﬁ  ed as or likely to 
be caused by staphylococci. B) Age-standardized 
admission ratios for community-onset control 
conditions. SSSS, staphylococcal scalded-skin 
syndrome.Community-onset Staphylococcal Disease, England
by staphylococci. This lack of data on the organisms that 
cause septicemia may  have masked an even greater in-
crease in staphylococcal septicemias.
For staphylococcal septicemia, staphylococcal pneu-
monia, abscess, furuncles and carbuncles, cellulitis, and 
bone and joint infections, both the admission rates and the 
extent of their rise increased with patient age. Among those 
>85 years of age, there was a 15-fold increase in admission 
rates for staphylococcal septicemia, an 8-fold increase in 
staphylococcal pneumonia, a 4-fold increase in abscesses 
and cellulitis, and a 2.7-fold increase in bone and joint infec-
tions. Nevertheless, major statistically signiﬁ  cant increases 
in admissions for community-onset staphylococcal septice-
mia, abscess, furuncles and carbuncles, and cellulitis were 
seen for all age groups. For staphylococcal pneumonia, 
statistically signiﬁ  cant increases were seen for those >16 
years of age, whereas for bone and joint infections, they 
were seen in all age groups except 5- to 15-year-olds. Pre-
dictably, impetigo and SSSS were seen primarily in those 
<16 years of age, and statistically signiﬁ  cant increases were 
conﬁ  ned to children (Table 2).
On the basis of PACT data, a major increase in prescrib-
ing for staphylococcal disease by general practitioners was 
evident (Figure 2). The ﬂ  oxacillin prescribing rate per 100 
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Table 2. Age-specific hospital admission rates (2003–04, per 100,000) and rate ratios (2003–04 vs. baseline) for invasive community-
onset staphylococcal infections, England* 
Age group, y
Infection All 4 5–14 15–44 45–64 65–74 75–84 !85
Baseline data 1989–90 
Abscess/cellulitis
 Admission 
 rate
149.3 110.1 45.1 123.2 149.5 216.1 349.5 634.3
 Rate  ratio 
 (95%  CI)
3.0
(2.9–3.0)
1.8
(1.7–1.9)
1.8
(1.7–1.9)
2.7
(2.6–2.8)
3.3
(3.2–3.4)
3.8
(3.6–3.9)
3.5
(3.4–3.7)
4.0
(3.8–4.3)
Staphylococcal septicemia
 Admission 
 rate
3.4 2.2 0.7 1.3 2.7 7.4 14.1 28.7
 Rate  ratio 
 (95%  CI)
6.5
(5.7–7.4)
3.8
(2.2–6.3)
5.5
(2.5–12.2)
6.4
(4.7–8.9)
4.6
(3.5–6.1)
5.4
(4.1–7.2)
7.7
(5.7–10.4)
15.2
(8.9–25.9)
Staphylococcal pneumonia
 Admission 
 rate
1.1 0.7 0.2 0.4 0.7 2.9 5.5 10.0
 Rate  ratio 
 (95%  CI)
5.0
(4.1–6–1)
1.2
(0.6–2.3)
1.3
(0.5–3.2)
4.2
(2.5–6.9)
4.2
(2.5–7.0)
6.0
(3.8–9.7)
9.0
(5.4–15.1)
8.2
(4.2–16.3)
Impetigo
 Admission 
 rate
2.2 24.9 4.2 0.5 0.2 0.1 0.3 0.4
 Rate  ratio 
 (95%  CI)
5.3
(4.6–6.2)
6.1
(5.0–7.3)
11.8
(7.6–18.4)
3.6
(2.3–5.4)
2.1
(0.9–4.7)
1.3
(0.3–4.7)
1.3
(0.4–4.1)
3.2
(0.4–28.2)
Bone and joint infections 
 Admission 
 rate
13.4 18.3 9.2 8.5 14.0 22.8 28.6 40.5
 Rate  ratio 
 (95%  CI)
1.6
(1.5–1.6)
1.2
(1.1–1.4)
1.0
(0.9–1.2)
1.4
(1.3 –1.5)
1.7
(1.5–1.8)
2.0
(1.8–2.3)
1.9
(1.7–2.2)
2.7
(2.2–3.4)
Baseline data 1995–96 
Staphylococcal scalded skin syndrome 
 Admission 
 rate
1.5 21.3 2.0 0.03 0.03 0.1 0.1 0.1
 Rate  ratio 
 (95%  CI)
4.9
(4.1–5.8)
6.4
(5.2–7.9)
3.7
(2.5–5.4)
1.7 ( 
0.5–5.8)
1.9
(0.3–10.2)
3.0
(0.3–29.3)
1.8
(0.2–20.4)
0.2
(0.0–1.6)
Cellulitis 
 Admission 
 rate
100.3 50.5 22.9 57.4 108.4 181.6 316.5 595.5
 Rate  ratio 
 (95%  CI)
2.0
(2.0–2.0)
2.2
(2.0–2.4)
1.5
(1.4–1.7)
2.0
(1.9–2.0)
2.0
(1.9–2.1)
2.0
(1.9–2.0)
2.0
(1.9–2.1)
2.0
(1.9–2.1)
Abscess
 Admission 
 rate
491.0 59.6 22.2 65.8 41.2 34.5 33.0 38.8
 Rate  ratio 
 (95%  CI)
1.9
(1.8–1.9)
1.6
(1.5–1.7)
1.5
(1.4–1.7)
2.1
(2.0–2.1)
1.8
(1.7–1.9)
1.7
(1.5–1.8)
1.7
(1.5–1.8)
1.5
(1.3–1.8)
* Years are financial years, April 1 to March 31. CI, confidence interval. RESEARCH
population was 4.0 prescriptions in 1991 and 7.3 in 2006 
(a 1.8-fold increase). The fusidic acid prescription rate per 
100 persons was 2.0 in 1991 and 5.0 in 2006 (a 2.5-fold in-
crease).
Discussion
We have identiﬁ  ed a major and previously undocu-
mented increase in community-onset staphylococcal dis-
ease. This increase has been ongoing for at least 15 years, 
since collection of HES data began in 1989, preceding the 
major (and largely separate) nosocomial increase in MRSA 
by several years (19). The increase has included a wide va-
riety of staphylococcal diseases, has affected all age groups, 
included both GP prescribing and hospital admissions, and 
was not matched by similar increases in admission rates for 
control conditions. There were increasing trends in admis-
sions for septicemia in general, but this increase may have 
been inﬂ  uenced by the rising incidence of staphylococcal 
septicemia. Although the increase in admissions has been 
marked, community-onset staphylococcal infections severe 
enough to merit admission remain comparatively rare. GP 
prescriptions for staphylococcal infections have increased 
to a lesser extent than admissions, but such prescriptions 
are very common.
Although we cannot be certain that S. aureus was the 
causative organism for all admissions identiﬁ  ed here in 
the HES data, the degree of certainty for those recorded 
as staphylococcal septicemia, staphylococcal pneumonia, 
and SSSS is high. S. aureus is also the most likely etiologic 
agent for abscesses, furuncles, and carbuncles (3), and bone 
and joint infections (6) and is a very common cause of cel-
lulitis (although β-hemolytic streptococci predominate) 
(5). S. aureus is the sole cause of bullous impetigo and the 
main agent of nonbullous impetigo, where, however, Strep-
tococcus pyogenes is sometimes isolated (20). In moderate 
climates such as in the United Kingdom, staphylococcal 
impetigo is more common, whereas the streptococcal form 
predominates in warmer and more humid climates (21).
National data on voluntary reporting of S. aureus 
bacteremia show a 2.5-fold increase from 1990 to 2004 
(an equivalent period to our study) (22). This included a 
2.1-fold increase in reports of methicillin-sensitive S. au-
reus (MSSA). Our hospitalization data show a much more 
marked increase in community-onset staphylococcal bac-
teremia. However, the voluntary reporting system could 
not distinguish between hospital- and community-acquired 
bacteremias during this period and therefore cannot give 
insight into trends in community-onset infections. This 
means that national surveillance of bacteremia could easily 
have missed a major increase in community-onset staphy-
lococcal bacteremia. A study from an Oxford hospital lab-
oratory with an estimated referral population of 600,000 
identiﬁ  ed 697 cases of S. aureus bacteremia when the sam-
ple was taken within 48 h of admission between 1997 and 
2003 but found no evidence of an increase in the numbers 
of these cases during the study period (23). Other research 
has shown that ≈50% of S. aureus bacteremia cases identi-
ﬁ  ed at the time of admission are not associated with clinical 
evidence of septicemia and are thus likely to result from 
contaminants (24). By contrast, our study includes >13,000 
admissions in which staphylococcal septicemia was identi-
ﬁ  ed as the main clinical reason for the admission and iden-
tiﬁ  es a major increase in these admissions over a longer 
period. Our study also covers a very much larger popula-
tion (all of England, ≈50 million persons). The trends in 
community-onset staphylococcal bacteremia are, in fact, 
only a small part of a wider trend of increasing hospitaliza-
tions for other more common staphylococcal infections and 
a marked increase in community prescribing for skin and 
soft tissue infections. Laboratory surveillance, however, 
tells us very little about trends in these conditions because 
most are not laboratory conﬁ  rmed.
Our hospital admission data relate to the primary rea-
son for admission, and the trends identiﬁ  ed are therefore for 
community-onset invasive disease rather than disease aris-
ing during periods of hospitalization. This does not neces-
sarily mean that infection was community acquired because 
infection may only become manifest after the patient is dis-
charged into the community (15). We were unable to assess 
whether the present diagnoses related to previous episodes 
of hospitalization. However, S. aureus is a common cause 
of infection, and it is unlikely that most of this increase 
relates to healthcare activity. Previous research has shown 
that most patients with community-onset MRSA and MSSA 
bacteremia had a previous history of hospitalization. (How-
ever, for MSSA, the average time since last discharge was 
>100 days, so most patients probably acquired the infection 
in the community [23]). Similarly, trends in community-on-
set osteomyelitis or abscesses may relate to hospital acqui-
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Figure 2. Crude general practitioner (GP) prescription rates (per 
100 population), England, 1991–2006. Community-onset Staphylococcal Disease, England
sition, for example, as complications of surgery, but most 
are not likely to be nosocomial. The trends in admissions 
for furuncles and carbuncles, cellulitis, impetigo, SSSS, 
and staphylococcal pneumonia are more likely to reﬂ  ect 
real increases in community-acquired infections. Changes 
in the likelihood of specifying an organism for septicemia 
are not a probable reason for the increase in staphylococ-
cal septicemia because the proportion of septicemias with a 
recorded organism (68% in 1989–90 and 65% in 2003–04) 
did not increase signiﬁ  cantly. Ascertainment bias resulting 
from increased awareness of MRSA may conceivably have 
led to increased recording of staphylococcal septicemia but 
is unlikely to have affected recording of community-onset 
abscesses and boils, cellulitis, impetigo, SSSS, or osteomy-
elitis because the doctors attending patients and the clerks 
who code the reasons for admission would be unlikely to 
associate these with MRSA. Similarly, increased awareness 
of MRSA cannot account for increases in GP prescribing of 
ﬂ  oxacillin and fusidic acid.
Our analysis showed a marked increase in admissions 
of adults for staphylococcal pneumonia. This condition has 
been linked to the production of PVL toxin (25), although 
nearly 90% of staphylococcal pneumonia cases are not as-
sociated with PVL production (26). Several outbreaks of 
PVL-associated infection in the United Kingdom have been 
well-publicized recently (27), but PVL-producing strains 
of staphylococci are rarely identiﬁ  ed in samples other than 
those from skin and soft tissue infections (26). Most skin 
and soft tissue infections, however, are not microbiologi-
cally investigated, and in those for which staphylococci are 
identiﬁ  ed, tests for PVL production are not usually conduct-
ed. Testing occurs at the national staphylococcal reference 
laboratory after referral of isolates. However, referral is usu-
ally based on suspicion about the isolate or made because 
of a local outbreak. Thus, surveillance can miss important 
increases in the occurrence of PVL-associated disease.
Analysis of routinely collected data on hospital admis-
sions and GP prescriptions has given a unique insight into 
the macroepidemiology of community-onset staphylococ-
cal disease, impossible through any other means. The large 
numbers of cases exclude chance as an explanation for the 
trends. Moreover, the data are representative of England 
because HES data cover all admissions in the country and 
PACT data cover all NHS GP prescriptions that are dis-
pensed. Although changes from ICD-9 to ICD-10 com-
plicated the analysis, the underlying trends in pathogenic 
staphylococcal infections remain clear, and the fact that no 
equivalent increases in admission rates for unrelated acute 
community-onset conditions occurred suggests that the 
increases in staphylococcal disease represent a real shift. 
The system for collecting national data on hospitalizations 
and GP prescriptions has remained essentially unchanged 
throughout the study period. The fact that all NHS hospitals 
in the country and all community pharmacists and dispens-
ing practices are obligated to use the systems means that 
the denominator can be accurately determined from census 
data, which allow measurement of rates. By contrast, in the 
national voluntary bacteremia reporting system, the size of 
the denominator is unknown and varies from year to year, 
depending on which laboratories participate. There are 
likely to be inconsistencies between hospitals in how di-
agnostic codes are applied in HES data and how conditions 
are chosen as the main reason for admission. The absence 
of major changes in the data collection method throughout 
the study period, however, means that the large increase in 
admissions for staphylococcal infections is highly unlikely 
to be an artifact.
Floxacillin has been the treatment of choice for sus-
pected staphylococcal infections in general practice since 
the 1970s, so a switch in prescribing from penicillin is not 
a credible explanation for increasing ﬂ  oxacillin-prescribing 
rates (12). We also note that the increases are in marked 
contrast to previously reported declines in consultation and 
antimicrobial prescribing rates for respiratory tract infec-
tion over this period (28). The increase in GP prescribing 
mirrors, but is greater than, a similar increase in S. aureus–
associated skin and soft tissues infections in outpatients 
in the United States; that increase is hypothesized to be 
caused by the emergence of community-acquired MRSA, 
but trends in prescribing in ambulatory care were not exam-
ined (29). Our data show admissions for skin and soft tissue 
infections have increased more sharply than GP prescribing 
for these conditions. This ﬁ  nding could reﬂ  ect an increase 
in the average severity of infections.
The yearly increases were relatively modest, but the 
cumulative effect is a major and previously unrecognized 
shift in the epidemiology of S. aureus. This trend may 
result from altered virulence or transmissibility of S. au-
reus in general or of particular strains; changes in the host 
that affect vulnerability (e.g., increasing levels of obesity 
and diabetes or of intravenous drug use) or transmission 
dynamics (e.g., increasing use of preschool child care); 
or changes in the environment, such as widespread use 
of antimicrobial agents or changes in hygiene behavior. 
However, these explanations are speculative, and our ig-
norance of the factors driving such a major change is wor-
risome, particularly in view of the international concerns 
about the emergence of community-acquired MRSA and 
serious PVL-related disease.
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